BioMoti, the cancer therapeutics co-development company, has completed an initial private finance round of £150,000 under the Seed Enterprise Investment Scheme (SEIS). The financing was led by the Oxford Technology OT(S)EIS Fund and an existing shareholder. The financing will be used to progress the Oncojan™ therapeutics delivery platform towards a regulatory compliant preclinical package that […]